Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Response to the Comment ‘Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019
Author(s): Maki Komiyama , Koji Hasegawa Added: 3 years ago
Thank you very much for your interesting and important comments on our review that discussed smoking cessation to limit the coronavirus disease 2019 (COVID-19) pandemic.1,2 As you pointed out, the reported number of hospitalised COVID-19 patients who are current or former smokers is small.3,4 One reason for this small number of smokers is that an unknown history of smoking may be treated as a non… View more

COVID-19
Response to the Comment ‘Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019
Author(s): Marco Rossato , Angelo Di Vincenzo Added: 3 years ago
We read with interest the paper by Komiyama and Hasegawa on the need for smoking cessation as a public health measure to limit the coronavirus disease 2019 (COVID-19) pandemic.1 It seems obvious to reiterate that smoking cessation is advisable to reduce many other severe conditions, such as chronic lung and cardiovascular diseases and some types of cancer, which are leading causes of morbidity… View more

COVID-19
Smoking Cessation as a Public Health Measure to Limit the Coronavirus Disease 2019 Pandemic
Author(s): Maki Komiyama , Koji Hasegawa Added: 3 years ago
The novel coronavirus disease 2019 (COVID-19) first occurred in December 2019 in Wuhan, Hubei Province, China, and has already evolved into a rapidly expanding pandemic. The WHO has declared COVID-19, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to be a public health emergency of international concern.1 Until effective therapeutics and vaccines become available… View more

Standards & Guidelines

COVID-19
Author(s): Giuliano Tocci , Lorenzo Castello , Massimo Volpe Added: 3 years ago
The renin–angiotensin system (RAS) has a key role in the maintenance of cardiovascular (CV) homeostasis, and water and electrolyte metabolism in healthy subjects.1 By contrast, the excess of angiotensin II in several diseases represents a pathophysiological mechanism that can promote or even accelerate atherosclerotic processes, cardiac and vascular hypertrophy, and kidney disease.1 In particular… View more

Prevention & Chronic Conditions
Author(s): Domenic A Sica Added: 3 years ago
Introduction Diabetes mellitus is rapidly increasing in its worldwide prevalence and is currently estimated to affect 7-8% of the US population.1 In 2005, 1.5 million new cases of diabetes were diagnosed in people aged 20 years or older in the US. In the not-so- distant past, type-2 diabetes mellitus was viewed as a seemingly benign condition, at least in the elderly, with little effect on life… View more

Prevention & Chronic Conditions
Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic
Author(s): M Rizzo , I Colomer-Asenjo , M Sutil-Vega , et al Added: 3 years ago
Aims: To assess the clinical and neurohormonal characteristics of patients eligible to sacubitril/valsartan (SV) attending to an outpatient heart failure clinic and describe variables related to SV prescription in real-life heart failure patients. Design and methods: We collected data from 119 consecutive patients attending our heart failure outpatient clinic between May 2018 and November 2018. … View more

Heart Failure
Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction
Author(s): M Rizzo , I Colomer-Asenjo , G Cabello-Molina , et al Added: 3 years ago
Aims: To describe the clinical characteristics, safety and tolerability profile, and discontinuation causes of sacubitril/valsartan (SV) treatment in patients attending an outpatient heart failure clinic. Design and methods: We collected data from 119 consecutive patients between May and November 2018. Variables were collected baseline and post-SV titration period. Results: 64 patients (53.8%)… View more

Heart Failure
Author(s): Derek V Exner Added: 3 years ago
Why Do We Need Risk Stratification Tools? Sudden death accounts for between 300,000 and 500,000 deaths each year in North America.1 Patients with a history of myocardial infarction (MI) have a four-fold higher risk of sudden death than those without such a history. Most sudden deaths in ambulatory populations result from life-threatening ventricular arrhythmias that lead to a cardiac arrest.2… View more

MI/ACS
Author(s): Alejandro de la Sierra Added: 3 years ago
Despite the presence of an artificial debate developed in the past decade1,2 focusing on calcium channel blockers and their role in the prevention and treatment of cardiovascular diseases, a huge amount of evidence has been created favouring this class of agents in the treatment of hypertension and associated cardiovascular diseases.3 Calcium channel blockers are divided into three classes, the… View more

Prevention & Chronic Conditions

Intervention
Recent Warnings about Antihypertensive Drugs and Cancer Risk: Where Do They Come From?
Author(s): Allegra Battistoni , Massimo Volpe Added: 3 years ago
Cardiovascular and neoplastic diseases are currently the main causes of mortality and morbidity in developed nations.1 These diseases often coexist in the same individual, worsening general condition, complicating therapeutic management and – from a different perspective – raising the issue of possible shared pathophysiological pathways between cardiovascular disease (CVD) and cancer. Many of the… View more

Prevention & Chronic Conditions